A Phase 2 Study of ALIMTA Plus Doxorubicin Administered Every 21 Days in Patients With Advanced Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Doxorubicin; Pemetrexed
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 29 Nov 2007 The expected completion date for this trial is now 1 Oct 2007.
- 29 Nov 2007 Status changed from in progress to completed according to ClinicalTrials.gov.
- 28 Jul 2006 Status change